Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERVGet Rating) in a report released on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on the stock. Zacks Investment Research raised shares of Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a report on Saturday, March 5th. HC Wainwright dropped their price objective on shares of Minerva Neurosciences to $5.00 and set a “buy” rating for the company in a report on Friday, March 4th.

Shares of NASDAQ:NERV opened at $0.70 on Tuesday. The firm has a fifty day moving average price of $0.75. Minerva Neurosciences has a one year low of $0.63 and a one year high of $3.54. The company has a market cap of $29.97 million, a P/E ratio of -0.59 and a beta of 0.93.

Minerva Neurosciences (NASDAQ:NERVGet Rating) last announced its quarterly earnings results on Tuesday, March 1st. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.08. Equities research analysts predict that Minerva Neurosciences will post -0.69 earnings per share for the current year.

Large investors have recently modified their holdings of the stock. Two Sigma Securities LLC purchased a new position in Minerva Neurosciences in the 3rd quarter worth $29,000. Rafferty Asset Management LLC purchased a new position in Minerva Neurosciences in the 3rd quarter worth $85,000. Bank of America Corp DE increased its position in shares of Minerva Neurosciences by 18.7% in the second quarter. Bank of America Corp DE now owns 42,895 shares of the biopharmaceutical company’s stock valued at $99,000 after acquiring an additional 6,749 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Minerva Neurosciences by 33.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 143,761 shares of the biopharmaceutical company’s stock valued at $250,000 after acquiring an additional 35,887 shares during the period. Finally, BlackRock Inc. increased its position in shares of Minerva Neurosciences by 3.7% in the fourth quarter. BlackRock Inc. now owns 506,457 shares of the biopharmaceutical company’s stock valued at $406,000 after acquiring an additional 18,087 shares during the period. Institutional investors own 55.03% of the company’s stock.

Minerva Neurosciences Company Profile (Get Rating)

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.

Further Reading

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.